Class of Stock [Axis]
Common Stock Par Value 0.001 Per Share [Member]
Warrants to Purchase Common Stock [Member]
Related and Nonrelated Parties [Axis]
Related Party [Member]
Nonrelated Party [Member]
Series B-1 Convertible Preferred Stock [Member]
Series B-2 Convertible Preferred Stock [Member]
Series B-3 Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Legal Entity [Axis]
Biofrontera Group [Member]
Investor [Member]
Statistical Measurement [Axis]
Maximum [Member]
Sale of Stock [Axis]
Private Placement [Member]
Minimum [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Financial Instrument [Axis]
2023 Purchase Warrants [Member]
Fair Value, Inputs, Level 3 [Member]
2022 Purchase Warrants [Member]
2022 Inducement Warrants [Member]
Biofrontera AG [Member]
Measurement Input Type [Axis]
Measurement Input, Share Price [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Option Volatility [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Dividend Payment [Member]
Long-Lived Asset, Class [Axis]
Manufacturing Equipment [Member]
Machinery Equipment [Member]
Computer Equipment [Member]
Furniture and Fixtures [Member]
Leasehold Improvements [Member]
Intangible Asset, Finite-Lived, Class [Axis]
Intellectual Property [Member]
Software [Member]
Asset Acquisition [Axis]
Biofrontera Group Acquisition [Member]
Debt Instrument [Axis]
Senior Secured Convertible Notes [Member]
Short-Term Debt, Type [Axis]
Convertible Notes Payable [Member]
Investment, Name [Axis]
Holder [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Purchase Agreement [Member]
Product and Service [Axis]
License [Member]
Earnout Agreement [Member]
Liability Classified [Member]
Equity Classified [Member]
Plan Name [Axis]
2021 Omnibus Incentive Plan [Member]
Location, Statement of Income, Balance [Axis]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities [Axis]
Common Stock Warrant [Member]
Common Stock Options and Restricted Stock Units [Member]
Unit Purchase Options [Member]
Series B Convertible Preferred Stock [Member]
Convertible Notes [Member]
New Lease Arrangement [Member]
Licensing Agreement [Member]
Accounting Standards Update [Axis]
ASC 855-10-25-1 [Member]
Segments [Axis]
Single Reportable Segment [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Information, Former Legal or Registered Name
Entity Listing, Par Value Per Share
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
ASSETS
Current assets:
Cash and cash equivalents
Investment, related party
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Other assets, related party
Total current assets
Inventories, long term
Property and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Operating lease liabilities
Accrued expenses and other current liabilities
Total current liabilities
Long-term liabilities:
Convertible notes payable, net
Warrant liabilities
Operating lease liabilities, non-current
Other liabilities
Total liabilities
Commitments and contingencies (see Note 17)
Stockholders’ equity:
Convertible Preferred Stock, $0.001 par value, 20,000,000 shares authorized; no Series B-1; 1,850 and 2,050 Series B-2; 6,498 and 6,593 Series B-3; 9,707 and ID="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCC
Common stock, $0.001 par value, 70,000,000 shares authorized; 14,206,126 and 11,648,323 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Product revenues, net
Operating expenses
Cost of revenues
Selling, general and administrative
Selling, general and administrative, related party
Patent remediation expense
Research and development
Total operating expenses
Loss from operations
Other income (expense)
Change in fair value of warrant liabilities
Change in fair value of investment, related party
Interest expense, net
Other income (expense), net
Total other income (expense)
Loss before income taxes
Income tax expense
Net loss
Loss per common share:
Basic
Diluted
Weighted-average common shares outstanding:
Basic
Diluted
Balance
Balance, shares
Conversion of Series B-2 Preferred into Common
Conversion of Series B-2 Preferred into Common, shares
Conversion of Series B-3 Preferred into Common
Conversion of Series B-3 Preferred into Common, shares
Conversion of Series C Preferred into Common
Conversion of Series C Preferred into Common, shares
Conversion of convertible notes into Common
Conversion of convertible notes into Common, shares
Stock based compensation
Net loss
Issuance of shares for restricted stock units
Issuance of shares for restricted stock units, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to cash flows used in operations:
Depreciation and amortization
Reduction in the carrying amount of right-of-use assets
Stock-based compensation
Non-cash interest expense
Allowance for credit losses
Change in fair value of warrant liabilities
Realized/unrealized (gain)/ loss in investment, related party
Loss from termination of operating leases
Changes in operating assets and liabilities:
Accounts receivable
Other receivables, related party
Prepaid expenses and other assets
Other assets, related party
Inventories
Accounts payable
Accounts payable, related parties, net
Operating lease liabilities
Accrued expenses and other liabilities
Cash flows used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Cash flows used in investing activities
Cash flows from financing activities
Proceeds from stockholder advances
Cash flows provided by financing activities
Net change in cash, cash equivalents
Cash, cash equivalents and restricted cash, at the beginning of the period
Cash, cash equivalents and restricted cash, at the end of the period
Supplemental disclosure of cash flow information
Interest paid
Income taxes paid, net
Supplemental non-cash financing activities
Addition of right-of-use assets in exchange for operating lease liabilities
Conversion of convertible note payable and PIK interest into common stock
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Overview
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Fair Value Disclosures [Abstract]
Fair Value Measurements
Revenue from Contract with Customer [Abstract]
Revenue
Cash and Cash Equivalents [Abstract]
Cash Balances and Statements of Cash Flows Reconciliation
Credit Loss [Abstract]
Accounts Receivable, net
Inventory Disclosure [Abstract]
Inventories
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets
Property, Plant, and Equipment [Abstract]
Property and Equipment, Net
Intangible Asset, Goodwill and Other [Abstract]
Intangible Assets, Net
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities
Debt Disclosure [Abstract]
Debt
Related Party Transactions [Abstract]
Related Party Transactions
Equity [Abstract]
Stockholders’ Equity
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans and Share-Based Payments
Earnings Per Share [Abstract]
Net Loss per Share
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Reporting
Subsequent Events [Abstract]
Subsequent Events
Basis for Preparation of the Financial Statements
Reclassification of Prior Year Presentation
The Nasdaq Stock Market, LLC (“Nasdaq”) Compliance
Use of Estimates
Recently Adopted or Issued Accounting Pronouncements
Schedule of Assets Measured at Fair Value On Recurring Basis
Schedule of Fair Value of Warrant Estimated by Using Black-Scholes Pricing Model Assumptions
Schedule of Changes in Fair Value of Warrant Liabilities
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Property and Equipment, Net
Schedule of Intangible Assets, Net
Schedule of Estimated Future Amortization Expense
Schedule of Accrued Expenses and Other Current Liabilities
Schedule of Warrants Outstanding
Schedule of Preferred Stock Issued and Outstanding
Schedule of Stock Option Activity
Schedule of Restricted Stock Units
Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share
Schedule of Future Commitments and Sublease Income
Segment Reporting [Table]
Segment Reporting [Line Items]
Schedule of Operating Segment
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Shares, Issued
Preferred Stock, Par or Stated Value Per Share
Investments
Proceeds from Sale of Intangible Assets
Variable consideration contingent
Net cash outflows from operations
Accumulated deficit
[custom:SalesMilestonePaymentsAmount-0]
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Share price
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Investment, related party
Total Liabilities
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price
Expiration term (in years)
Warrant outstanding, measurement input
Fair value at beginning of period
Fair value at end of period
Common shares owned
Warrants to purchase shares of common stock
Warrants expiration date
Exercise price of warrants
Long-term restricted cash
Total cash, cash equivalents, and restricted cash shown on the consolidated statements of cash flows
Allowance for credit losses
Inventory, short-term:
Finished product
Work in process
Raw materials
Total inventory, short-term
Inventory, long term
Finished product
Work in process
Raw materials
Total inventory, long-term
Total inventories
Inventory write-down
Schedule Of Prepaid Expenses And Other Current Assets
Value-added tax receivable
Licenses
Clinical trials
Insurance
Inventory
Other
Total
Property and equipment, gross
Less: Accumulated depreciation
Property and equipment, net
Depreciation expense
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Intangible assets
Accumulated amortization
Intangible assets, net
July – December 2026
2027
2028
2029
2030
Thereafter
Intangible assets
Estimated useful life
Amortization expense
Impairment of intangible assets
Employee compensation and benefits
Professional fees
Patent remediation expense (See Note 17. Commitments and Contingencies – Legal Proceedings)
Research and development
Product revenue allowances and reserves
Other
Total
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Debt principal amount
Debt instrument interest rate
Debt instrument interest rate increase
Conversion price
Threshold percentage of stock price trigger
Stock ownership percentage
Debt issuance cost
Conversion of convertible notes into common
Interest expense
Short term debt average outstanding amount
Unamortized issuance cost
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Royalty percentage
Revenues
Other receivables
Other assets
Earnouts related to sales
Debt instrument face amount
Debt outstanding
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares
Exercise Price
Expiration Date
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Conversion price
Dividends payable, amount per share
Common Stock, Shares Authorized
Preferred Stock, Shares Authorized
Restricted stock units
Sale of stock, description
Shares conversion of common stock
Debt instrument conversion price
Warrants exercised
Warrants exercised price, per share
Stock Issued During Period, Shares, Conversion of Units
Debt Instrument, Face Amount
Debt conversion amount
Debt conversion shares issued
Number of Shares Outstanding, Beginning Balance
Weighted Average Exercise Price, Beginning Balance
Weighted Average Remaining Contractual Life (in Years), Outstanding
Aggregate Intrinsic Value, Outstanding, Balance
Number of Shares Outstanding, Granted
Weighted Average Exercise Price, Granted
Number of Shares Outstanding, Exercised
Weighted Average Exercise Price, Exercised
Number of Shares Outstanding, Canceled or forfeited
Weighted Average Exercise Price, Canceled or forfeited
Number of Shares Outstanding, Ending Balance
Weighted Average Exercise Price, Ending Balance
Aggregate Intrinsic Value, Outstanding, Balance
Number of Shares Execisable, Ending Balance
Weighted Average Exercise Price Options Exercisable, Ending Balance
Weighted Average Remaining Contractual Life (in Years), Exercisable
Aggregate Intrinsic Value, Exercisable, Balance
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares outstanding, Beginning balance
Number of shares weighted average grant date fair value, Beginning balance
Number of shares outstanding, Awarded
Number of shares weighted average grant date fair value, Awarded
Number of shares outstanding, Vested
Number of shares weighted average grant date fair value, Vested
Number of shares outstanding, Canceled or forfeited
Number of shares weighted average grant date fair value, Canceled or forfeited
Number of shares outstanding, Ending balance
Weighted average remaining contractual life (in years) outstanding, Balance
Number of shares weighted average grant date fair value, Ending balance
Maximum contractual term
Number of shares authorized for issuance
Shares available for future grant
Exercise price
Risk free rate
Volatility
Dividend yield
Expected Term
Share based compensation expenses
Unrecognized compensation cost
Compensation cost recognized, weighted average period
Weighted average common shares outstanding, basic
Weighted average common shares outstanding, diluted
Net loss per share, basic
Net loss per share, diluted
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
July – December 2026
2027
2028
2029
2030
Thereafter
Total future minimum lease payments
Less imputed interest
Total lease liability
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Security deposit
Operating lease cost
Cash paid for amounts included in the measurement of operating lease liabilities
Weighted -average remaining lease term (in years)
Weighted -average discount rate
Licensing fee
Sales milestone payments
Royalties percentage related to royalties
Estimated remediation cost
Accrued remediation liability
Revenues, net
Operating expenses:
Cost of revenues
Direct sales
Sales support
General and administrative
Manufacturing related
Regulatory and product affairs
Other operating expenses
Total operating expenses
Other income (expense), net
Number of operating segment
Number of reportable segments not disclosed flag
Subsequent Event [Table]
Subsequent Event [Line Items]
Shares converted
Shares conversion shares issued
Warrants to Purchase Common Stock [Member]
Common Stock Par Value 0.001 Per Share [Member]
Warrant liabilities non current.
Inventory finished goods noncurrent.
Inventory work in process noncurrent.
Inventory raw materials and supplies noncurrent
Inventory current and noncurrent
Prepaid Expense and Other Assets Current [Text Block]
Prepaid licenses.
Prepaid clinical trials.
Patent remediation expense.
Prepaid inventory.
Machinery Equipment [Member]
Manufacturing Equipment [Member]
Biofrontera Group Acquisition [Member]
Stock issued during period shares conversion of unit.
Accrued patent remediation expense.
Amount of research and development incurred but not yet paid, due within one year or the normal operating cycle, if longer.
Product revenue allowances and reserves.
Stock issued during period value conversion of units others.
Stock issued during period shares conversion of unit others.
Senior Secured Convertible Notes [Member]
Holder [Member]
Conversion of series C preferred into common stock value.
Conversion of series C preferred into common stock share.
Royalty Percentage.
Biofrontera Group [Member]
Purchase Agreement [Member]
Earnout Agreement [Member]
Non-cash Interest Expense.
Liability Classified [Member]
Equity Classified [Member]
Series C Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Series B-2 Convertible Preferred Stock [Member]
Series B-3 Convertible Preferred Stock [Member]
Asset acquisition consideration transferred contingent consideration variable.
Sales milestone payments amount.
Biofrontera AG [Member]
2022 Purchase Warrants [Member]
2022 Inducement Warrants [Member]
2023 Purchase Warrants [Member]
2021 Omnibus Incentive Plan [Member]
Nasdaq Listing Compliance [Policy Text Block]
New Lease Arrangement [Member]
Lessee operating lease liability payments due after year four.
Licensing Agreement [Member]
Revenue performance obligation related to royalties percentage.
Remediation cost.
ASC 855-10-25-1 [Member]
Cost of revenues.
Direct sales expense.
Sales support expenses.
Regulatory and product affairs
Single Reportable Segment [Member]
Number of reportable segments not disclosed flag
Software [Member]
Selling, general and administrative, related party.
Finite lived intangible assets amortization expense after year four.
Accrued remediation liability.
Series B-1 Convertible Preferred Stock [Member]
Common Stock Warrant [Member]
Common Stock Options and Restricted Stock Units [Member]
Unit Purchase Options [Member]
Series B Convertible Preferred Stock [Member]
Convertible Notes [Member]
Working capital line of credit.
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Costs and Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Shares, Outstanding
Income (Loss) from Equity Method Investments
Gain (Loss) on Contract Termination
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Due from Other Related Parties, Current
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Current Assets
Increase (Decrease) in Inventories
Increase (Decrease) in Accounts Payable, Trade
Increase (Decrease) in Operating Lease Liability
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Inventory Disclosure [Text Block]
Investments, Fair Value Disclosure
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Accounts Receivable, Allowance for Credit Loss, Current
InventoryFinishedGoodsNoncurrent
InventoryWorkInProcessNoncurrent
InventoryRawMaterialsAndSuppliesNoncurrent
InventoryCurrentAndNoncurrent
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
Intangible Asset, Finite-Lived, after Accumulated Amortization
Intangible Asset, Finite-Lived, Acquired
AccruedResearchAndDevelopment
Other Accrued Liabilities, Current
Preferred Stock, Convertible, Conversion Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Operating Lease, Liability
CostOfRevenues
Operating Expenses